HDAC7 (Histone Deacetylase 7) is a class IIa histone deacetylase that primarily functions as a signal-responsive transcriptional coregulator rather than a high-turnover catalytic deacetylase. In the nervous system, HDAC7 plays important roles in neuronal development, synaptic plasticity, and stress response regulation. The enzyme is unique among HDACs due to its relatively low intrinsic catalytic activity and its prominent role as a scaffolding protein that recruits chromatin-modifying complexes to specific genomic loci. HDAC7 dysregulation has been implicated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, making it a potential therapeutic target.
| HDAC7 Protein | |
|---|---|
| Full Name | Histone Deacetylase 7 |
| UniProt ID | [Q8WUI4](https://www.uniprot.org/uniprotkb/Q8WUI4) |
| Gene Symbol | HDAC7 |
| Chromosomal Location | 12q13.12 |
| Protein Length | 669 amino acids |
| Molecular Weight | ~75 kDa |
| Protein Class | Class IIa histone deacetylase |
| Subcellular Localization | Nucleus/Cytoplasm (dynamic) |
| Expression | Neurons, glia, widespread |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease |
HDAC7 is a 669 amino acid protein with a molecular weight of approximately 75 kDa. The protein contains distinct N-terminal and C-terminal domains that mediate its diverse functions.
N-terminal Regulatory Domain (1-450 amino acids): This large domain contains multiple protein-protein interaction motifs:
Deacetylase Domain (480-669 amino acids): The C-terminal catalytic-like domain exhibits relatively low intrinsic deacetylase activity compared to class I HDACs. Key features include:
Phosphorylation-dependent shuttling: HDAC7 contains multiple serine residues (Ser155, Ser181, Ser321, Ser479) that are phosphorylated by kinases including CaMKIV, PKD, and MST1. Phosphorylation creates 14-3-3 binding sites, promoting nuclear export.
Nuclear localization signal (NLS): Located in the N-terminal domain, mediates nuclear import.
Nuclear export signal (NES): Multiple leucine-rich sequences enable CRM1-dependent export.
HDAC7 is characterized as a "pseudodeacetylase" due to its low catalytic activity. The enzyme:
HDAC7 regulates gene expression through multiple mechanisms:
Corepressor recruitment: HDAC7 recruits chromatin-modifying complexes to specific gene promoters, promoting histone deacetylation and transcriptional repression. Key partners include:
Signal-dependent shuttling: In response to cellular signaling:
Synaptic plasticity: HDAC7 regulates genes involved in:
Neuronal development: Controls:
Stress response: Modulates:
HDAC7 is widely expressed in the nervous system:
HDAC7 contributes to AD pathophysiology through epigenetic dysregulation:
Transcriptional drift: In AD brains, HDAC7 shows altered nuclear-cytoplasmic distribution, contributing to aberrant gene expression patterns characteristic of the disease.
Synaptic gene dysregulation: HDAC7 represses synaptic plasticity genes including BDNF, synapsin, and glutamate receptors. Dysregulated HDAC7 contributes to synaptic dysfunction.
Histone acetylation changes: Global histone acetylation alterations in AD correlate with HDAC7 dysregulation.
Therapeutic implications: HDAC inhibitors show promise in AD models, though isoform selectivity remains a goal.
HDAC7 is implicated in PD through:
Dopaminergic neuron survival: HDAC7 levels affect viability of dopaminergic neurons in the substantia nigra.
Alpha-synuclein interaction: HDAC7 may regulate genes involved in alpha-synuclein processing and aggregation.
Mitochondrial dysfunction: HDAC7 regulates PGC-1α and mitochondrial biogenesis genes.
Neuroinflammation: HDAC7 modulates microglial inflammatory responses.
HDAC7 plays complex roles in HD:
Polyglutamine pathology: HDAC inhibitors ameliorate polyglutamine-induced phenotypes in model systems.
Transcription factor dysregulation: HDAC7 interacts with REST (RE1-Silencing Transcription Factor), which is disrupted in HD.
Gene expression: HDAC7 contributes to the widespread transcriptional dysfunction observed in HD.
Amyotrophic Lateral Sclerosis (ALS): Altered HDAC7 expression in motor neurons.
Retinal degeneration: HDAC7 contributes to excitotoxicity-induced retinal ganglion cell death.
Multiple sclerosis: Role in demyelination and neuroinflammation.
Multiple serine residues are phosphorylated:
Phosphorylation promotes nuclear export via 14-3-3 binding.
HDAC7 itself can be acetylated, affecting:
HDAC7 undergoes ubiquitination:
HDAC7 can be sumoylated, affecting:
Pan-inhibitors: Affect HDAC7 along with other isoforms:
Class IIa-selective: Target the class IIa HDACs:
Emerging selective modulators: Target HDAC7-specific functions
Cancer therapy: HDAC inhibitors approved for T-cell lymphoma
Neurodegeneration: Clinical trials ongoing for AD, HD, and PD
Challenges: Achieving isoform selectivity remains difficult
Isoform-selective inhibition: Developing compounds that specifically target HDAC7's scaffolding functions rather than catalytic activity.
Protein-protein interaction inhibitors: Blocking HDAC7's interactions with Mef2, NCoR, or 14-3-3.
Degraders: PROTAC-based approaches to selectively degrade HDAC7.
Nuclear/cytoplasmic ratio: HDAC7 localization as a disease biomarker
Phosphorylation status: p-HDAC7 levels in cerebrospinal fluid
Gene expression signatures: HDAC7 target gene expression patterns
HDAC7 is a class IIa histone deacetylase with unique structural and functional properties. Unlike catalytic HDACs, HDAC7 primarily functions as a signal-responsive transcriptional coregulator that shuttles between nucleus and cytoplasm in response to cellular signaling. In the nervous system, HDAC7 regulates genes involved in synaptic plasticity, neuronal development, and stress responses. Dysregulation of HDAC7 contributes to neurodegenerative disease pathogenesis through transcriptional dysregulation, and the enzyme represents a potential therapeutic target. While pan-HDAC inhibitors have shown promise in preclinical models, achieving HDAC7 isoform-selectivity remains an important goal for future drug development.